Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Race Oncology Ltd. ( (AU:RAC) ).
Race Oncology Ltd has issued 941,090 fully paid ordinary shares following the cashless exercise of 4,000,000 unlisted options. This issuance allows the new shares to be traded immediately under section 708A(5) of the Corporations Act, indicating compliance with relevant legal provisions. The company is also awaiting a response from the Human Research Ethics Committee for its RAC-020 lung cancer trial, which could impact its ongoing clinical programs.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed Phase 3 clinical biopharmaceutical company focused on cancer care. Its lead asset, RCDS1 (E,E-bisantrene), is an anticancer agent targeting cancer growth regulator MYC through G4-DNA & RNA binding. The company is advancing RCDS1 for multiple oncology indications, including acute myeloid leukemia and non-small cell lung cancer, and is exploring partnerships to enhance global access to its treatments.
Average Trading Volume: 546,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
See more insights into RAC stock on TipRanks’ Stock Analysis page.